Association of Perioperative Glucagon-like Peptide-1 Receptor Agonist Use and Postoperative Outcomes.

IF 7.5 1区 医学 Q1 SURGERY
Annals of surgery Pub Date : 2025-04-01 Epub Date: 2024-12-20 DOI:10.1097/SLA.0000000000006614
Seth Z Aschen, Ashley Zhang, Gillian M O'Connell, Sophia Salingaros, Caroline Andy, Christine H Rohde, Jason A Spector
{"title":"Association of Perioperative Glucagon-like Peptide-1 Receptor Agonist Use and Postoperative Outcomes.","authors":"Seth Z Aschen, Ashley Zhang, Gillian M O'Connell, Sophia Salingaros, Caroline Andy, Christine H Rohde, Jason A Spector","doi":"10.1097/SLA.0000000000006614","DOIUrl":null,"url":null,"abstract":"<p><strong>Objective: </strong>To assess rates of surgical complications and postoperative readmission in diabetic patients with and without active perioperative prescriptions for glucagon-like peptide-1 receptor agonist (GLP-1 RA) medications.</p><p><strong>Background: </strong>With the rapid growth of GLP-1 RA use in the United States, it is important to understand the potential effect of these drugs on surgical outcomes broadly.</p><p><strong>Methods: </strong>In this retrospective, observational cohort analysis, patients with a diagnosis of type 1 or type 2 diabetes undergoing a surgical procedure at a multicenter quaternary-care health care system between February 2020 and July 2023 were included. Propensity score matching was performed between procedures in patients with and without an active GLP-1 RA prescription. The primary outcome was 30-day readmission, and secondary outcomes were documented dehiscence, infection, hematoma, and bleeding within 180 days after surgery.</p><p><strong>Results: </strong>Among 74,425 surgical procedures in 21,772 patients included in the analysis, 27.2% were performed in the setting of an active GLP-1 RA prescription. In 13,129 patients [48.0% men, 52.0% women; median (interquartile range) age, 67 (57, 75)], 35,020 procedures were propensity score matched. After matching, the active GLP-1 RA prescription group had a significantly reduced risk of 30-day readmission [relative risk (RR): 0.883; 95% CI: 0.789-0.987; P = 0.028; number needed to treat (NNT): 219; 95% CI: 191-257], postoperative wound dehiscence (RR: 0.711; 95% CI: 0.577-0.877; P = 0.001; NNT: 266; 95% CI: 202-391), and postoperative hematoma (RR: 0.440; 95% CI: 0.216-0.894; P = 0.023; NNT: 1786; 95% CI: 652-2416). No significant differences were seen in rates of infection and bleeding.</p><p><strong>Conclusions: </strong>An active perioperative GLP-1 RA prescription in patients with diabetes was associated with significant reductions in risk-adjusted readmission, wound dehiscence, and hematoma, and no difference in infection and bleeding rates. Further study is warranted to elucidate any causal association.</p>","PeriodicalId":8017,"journal":{"name":"Annals of surgery","volume":" ","pages":"600-607"},"PeriodicalIF":7.5000,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Annals of surgery","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1097/SLA.0000000000006614","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/12/20 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"SURGERY","Score":null,"Total":0}
引用次数: 0

Abstract

Objective: To assess rates of surgical complications and postoperative readmission in diabetic patients with and without active perioperative prescriptions for glucagon-like peptide-1 receptor agonist (GLP-1 RA) medications.

Background: With the rapid growth of GLP-1 RA use in the United States, it is important to understand the potential effect of these drugs on surgical outcomes broadly.

Methods: In this retrospective, observational cohort analysis, patients with a diagnosis of type 1 or type 2 diabetes undergoing a surgical procedure at a multicenter quaternary-care health care system between February 2020 and July 2023 were included. Propensity score matching was performed between procedures in patients with and without an active GLP-1 RA prescription. The primary outcome was 30-day readmission, and secondary outcomes were documented dehiscence, infection, hematoma, and bleeding within 180 days after surgery.

Results: Among 74,425 surgical procedures in 21,772 patients included in the analysis, 27.2% were performed in the setting of an active GLP-1 RA prescription. In 13,129 patients [48.0% men, 52.0% women; median (interquartile range) age, 67 (57, 75)], 35,020 procedures were propensity score matched. After matching, the active GLP-1 RA prescription group had a significantly reduced risk of 30-day readmission [relative risk (RR): 0.883; 95% CI: 0.789-0.987; P = 0.028; number needed to treat (NNT): 219; 95% CI: 191-257], postoperative wound dehiscence (RR: 0.711; 95% CI: 0.577-0.877; P = 0.001; NNT: 266; 95% CI: 202-391), and postoperative hematoma (RR: 0.440; 95% CI: 0.216-0.894; P = 0.023; NNT: 1786; 95% CI: 652-2416). No significant differences were seen in rates of infection and bleeding.

Conclusions: An active perioperative GLP-1 RA prescription in patients with diabetes was associated with significant reductions in risk-adjusted readmission, wound dehiscence, and hematoma, and no difference in infection and bleeding rates. Further study is warranted to elucidate any causal association.

围手术期胰高血糖素样肽-1受体激动剂使用与术后预后的关系。
目的:评估糖尿病患者围手术期是否积极服用GLP-1 RA药物的手术并发症和术后再入院率。背景:随着胰高血糖素样肽-1受体激动剂(GLP-1 RA)在美国使用的快速增长,广泛了解这些药物对手术结果的潜在影响非常重要。方法:在这项回顾性、观察性队列分析中,纳入了2020年2月至2023年7月在多中心四级医疗保健系统接受手术治疗的1型或2型糖尿病患者。在有和没有有效GLP-1 RA处方的患者之间进行倾向评分匹配。主要终点是30天再入院,次要终点是手术后180天内记录的裂开、感染、血肿和出血。结果:在纳入分析的21,772例患者的74,425例手术中,27.2%是在有效GLP-1 RA处方的情况下进行的。13129例患者35,020例手术(男性48.0%,女性52.0%;年龄中位数[IQR], 67[57,75])与倾向评分相匹配。匹配后,有效GLP-1 RA处方组患者30天再入院风险显著降低(RR, 0.883;95% ci, 0.789-0.987;P = 0.028;例数十分,219;95% CI, 191-257),术后伤口裂开(RR, 0.711;95% ci, 0.577-0.877;P = 0.001;例数十分,266;95% CI, 202-391)和术后血肿(RR, 0.440;95% ci, 0.216-0.894;P = 0.023;例数十分,1786;95% ci, 652-2416)。感染和出血发生率无显著差异。结论:糖尿病患者围手术期积极的GLP-1 RA处方与风险调整后再入院、伤口裂开和血肿的显著降低相关,感染和出血率无差异。有必要进一步研究以阐明任何因果关系。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Annals of surgery
Annals of surgery 医学-外科
CiteScore
14.40
自引率
4.40%
发文量
687
审稿时长
4 months
期刊介绍: The Annals of Surgery is a renowned surgery journal, recognized globally for its extensive scholarly references. It serves as a valuable resource for the international medical community by disseminating knowledge regarding important developments in surgical science and practice. Surgeons regularly turn to the Annals of Surgery to stay updated on innovative practices and techniques. The journal also offers special editorial features such as "Advances in Surgical Technique," offering timely coverage of ongoing clinical issues. Additionally, the journal publishes monthly review articles that address the latest concerns in surgical practice.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信